HEALSAFE · Health-Active Responsive Materials: Development, Stability, Safety, and Fate Evaluation in Complex Biological Media
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-09-01 → 2030-08-31
- Финансиране от ЕС
- 1 412 820 €
- Участници
- 11
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Адаптивни материали за наномедицина се разработват, за да преодолеят бариерите в тъкани при хронични рани или тумори. Те помагат за по-ефективно доставяне на лекарства и подобряване на терапията в сложни биологични среди.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
Pathological tissues, such as chronic wounds, carcinogenic burns, and solid tumors, are characterized by a profoundly remodeled extracellular matrix (ECM) that poses a physical barrier to nanomedicine penetration. These environments are further complicated by hostile microconditions, including oxidative stress, acidic pH, enzymatic dysregulation, and chronic inflammation, all of which hinder healing and reduce therapeutic efficacy. Overcoming the formulation challenges and navigating the physiological and immunological barriers within these diseased microenvironments represents a defining frontier for next-generation nanotherapeutics.HEALSAFE pioneers the development of dynamic, adaptive materials that emulate the responsiveness and intelligence of living tissues. With a strong translational focus and rigorous preclinical validation, HEALSAFE is intended to enhance workforce training and readiness for the era of personalized, responsive medicine.Key objectives include: (i) Design and synthesis of a modular library of microenvironment-responsive materials and hybrid systems with tunable physicochemical properties for targeted therapeutic applications; (ii) Development and optimization of encapsulation and controlled release mechanisms tailored to complex biological environments; (iii) Evaluation of biocompatibility, safety, and cellular interactions using advanced in vitro 2D and 3D tissue models; (iv) Preclinical demonstration of therapeutic efficacy, biodistribution, and safety in validated in vivo models of wound healing and other relevant pathological conditions; (v) Promotion of international and transdisciplinary collaboration, inter-sectoral knowledge exchange, and capacity building through targeted dissemination and training initiatives. By integrating novel self-assembled stimuli-responsive biomaterials with precision medicine strategies, HEALSAFE sets the stage for transformative advances in nanotherapeutic design and clinical translation.
Оригинален текст от CORDIS (на английски).
Участници
- CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS · ParisКоординаторФранция
- FERENTIS · VilniusЛитва
- FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA · GenovaИталия
- Faculdade de Farmácia da Universidade de Lisboa · LisboaПортугалия
- INSTITUTUL DE CHIMIE MACROMOLECULARA PETRU PONI · IasiРумъния
- INSTITUTUL REGIONAL DE ONCOLOGIE IASI · IasiРумъния
- OFS LIPID LEGENDS GMBH · WIENАвстрия
- Student Science, s.r.o. · Horní PodlužíЧехия
- The Institute of the Chemistry of Plant Substances named acad. S. Yu. Yunusov · TashkentУзбекистан
- UNIVERSIDADE NOVA DE LISBOA · LisboaПортугалия
- VALSTYBINIS MOKSLINIU TYRIMU INSTITUTAS FIZINIU IR TECHNOLOGIJOS MOKSLU CENTRAS · VilniusЛитва
Връзки
Данни: CORDIS, © Европейски съюз